K36 THERAPEUTICS
K36 Therapeutics mission to translate epigenetic modulation of oncogenic pathways into first-in-class small molecule therapies.
K36 THERAPEUTICS
Social Links:
Industry:
Biotechnology Therapeutics
Founded:
2021-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.k36tx.com
Status:
Active
Email Addresses:
[email protected]
Total Funding:
30 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Content Delivery Network Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS
Similar Organizations
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Remix Therapeutics
Remix Therapeutics is a biotechnology company.
Current Advisors List
Current Employees Featured
Investors List
F-Prime Capital
F-Prime Capital investment in Series A - K36 Therapeutics
Eight Roads Ventures
Eight Roads Ventures investment in Series A - K36 Therapeutics
Atlas Venture
Atlas Venture investment in Series A - K36 Therapeutics
Official Site Inspections
http://www.k36tx.com Semrush global rank: 5.8 M Semrush visits lastest month: 1.43 K
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.107
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "K36 Therapeutics"
About Us - K36tx
Disciplined. Resourceful. Intellectually Curious. United in our focus to improve the lives of cancer patients with unmet medical needs.See details»
Leadership | K36tx
President, Chief Executive Officer, K36 Board Member. Benjamin Winograd, MD, Ph.D. Chief Medical OfficerSee details»
K36 Therapeutics - Crunchbase Company Profile & Funding
Organization. K36 Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Contact Email [email protected]; โฆSee details»
K36 Therapeutics, Inc. | LinkedIn
K36 Therapeutics, Inc. Biotechnology Research Cambridge, Massachusetts 1,361 followers Translating epigenetic modulation of oncogenic pathways NSD2 / MMSET into first-in-class โฆSee details»
K36 Therapeutics Named โOverall BioPharma Startup of the
CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- K36 Therapeutics (โK36โ) has been selected as โOverall BioPharma Startup of the Yearโ in the third annual BioTech Breakthrough โฆSee details»
K36 Therapeutics - Overview, News & Similar companies - ZoomInfo
Apr 11, 2023 View K36 Therapeutics (www.k36tx.com) location in Massachusetts, United States , revenue, industry and description. Find related and similar companies as well as employees โฆSee details»
K36 Therapeutics Announces $70 Million Series B Financing to โฆ
Jun 28, 2023 Founded in February 2021, K36 is a privately held biotech company. Our mission is to translate epigenetic modulation of oncogenic pathways into first-in-class small molecule โฆSee details»
K36 Therapeutics
K36txโs lead candidate, KTX-1001, is a selective inhibitor of the histone methyltransferase MMSET which is overexpressed in around 20% of multiple myeloma patients. K36tx is โฆSee details»
Board of Directors | K36tx
President, Chief Executive Officer, K36 Board Member. Michael Heffernan. Independent Director K36 Board MemberSee details»
K36 Therapeutics - PitchBook
K36 Therapeutics General Information Description. Developer of small molecule therapeutics designed to treat cancer. The company leverages technology to develop orally bioavailable small molecule and selective inhibitors by โฆSee details»
K36 Therapeutics Named โOverall BioPharma Startup of the
Nov 8, 2023 Founded in February 2021, K36 is a privately held biotech company. Our mission is to translate epigenetic modulation of oncogenic pathways into first-in-class small molecule โฆSee details»
K36 Therapeutics Announces Presentation on KTX-1001 for โฆ
Dec 4, 2023 Poster to be presented Sunday, December 10, 2023. CAMBRIDGE, Mass., Dec. 4, 2023 /PRNewswire/ -- K36 Therapeutics, Inc. ("K36"), a clinical-stage biotech company โฆSee details»
K36 Therapeutics Named โOverall BioPharma Startup of the Yearโ โฆ
Nov 8, 2023 UN predicts world economic growth at subdued 2.8% in 2025. The world economy resisted battering by conflicts and inflation last year and is expected to grow a subdued 2.8% โฆSee details»
K36 Therapeutics - VentureRadar
"K36's lead candidate is KTX-1001, an orally bioavailable small molecule and a selective inhibitor of the MMSET gene, which is overexpressed in up to 20% of multiple myeloma patients due to โฆSee details»
Benjamin Winograd - K36tx
Dr. Winograd began his career at the European Organization for Research and Treatment of Cancer (EORTC) and has held positions of increasing responsibility, including Director of โฆSee details»
K36 Therapeutics, Inc. (K36 Therapeutics, Inc.) - ่ฏ็ฉ็ฎก็บฟ_ไธๅฉ_ไธด โฆ
Poster to be presented Sunday, December 10, 2023 CAMBRIDGE, Mass., Dec. 4, 2023 /PRNewswire/ -- K36 Therapeutics, Inc. ("K36"), a clinical-stage biotech company focused on โฆSee details»
Investors - K36tx
2024 © K36 Therapeutics All rights reserved. bottom of pageSee details»
KTX-1001 - Drug Targets, Indications, Patents - Synapse - Patsnap
Inactive Organization-Drug Highest Phase Phase 1. First Approval Date-Regulation Orphan Drug (US) Login to view timeline. ... For more information please visit: LinkedIn K36 COMPANY โฆSee details»
Press Releases - K36tx
Jun 28, 2023 K36 Therapeutics Announces Multiple Poster Presentations Highlighting the First Clinical Data for KTX-1001 and Other Developmental Compounds at the 66th American โฆSee details»